# Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis

> **NCT06441006** · PHASE2,PHASE3 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 400 (estimated)

## Conditions studied

- Tuberculosis, Pulmonary
- Tuberculosis, Multidrug-Resistant
- Tuberculosis, MDR

## Interventions

- **DRUG:** Bedaquiline
- **DRUG:** Linezolid
- **DRUG:** Pretomanid
- **DRUG:** Moxifloxacin
- **DRUG:** Control Arm FQ-S MDR/RR-TB regimen, designed according to latest international guidelines

## Key facts

- **NCT ID:** NCT06441006
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-03
- **Primary completion:** 2031-08
- **Final completion:** 2031-08
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-01-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441006, "Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06441006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*